Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances

Cartesian Therapeutics, Inc.

2026-Q1 EPS reported -$1.46 revenue$78,000

Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.
Cash, equivalents & restricted cash $120.4M as of March 31; raised $14.6M via ATM in Q1.
Phase 3 AURORA trial enrollment continues; Phase 2 TRITON in myositis initiated; HELIOS pediatric trial progress.
R&D expenses $19.5M (up 33% YoY) due to AURORA; G&A $7.1M (down 14% YoY).
Cash runway expected into mid-2027, supporting completion of Phase 3 AURORA trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Cartesian Therapeutics, Inc. reported three months ended March 31, 2026 results: net income -39,200,000, EPS -1.46.

Period: three months ended March 31, 2026
Net income: -39,200,000
EPS: -1.46

Exact text from the filing

Net loss was $39.2 million, or $1.46 net loss per share allocable to common stockholders (basic), for the three months ended March 31, 2026, compared to net loss of $17.7 million, or $0.68 net loss per share allocable to common stockholders (basic), for the three months ended March 31, 2025.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-26-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.